12.87

28.32% 2.84

Pre-market: 12.58 -0.29 -2.25%

Day One Biopharmaceuticals Inc (DAWN)

Overview News Price History Option Chain Financials Discussions Forecast

Day One Biopharmaceuticals Inc stock is traded at $12.87, with a volume of 12.25M. It is up +28.32% in the last 24 hours and up +19.83% over the past month. Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.

Previous Close:

$10.03

Open:

$10.12

24h Volume:

12.25M

Relative Volume:

4.70

Market Cap:

$1.33B

Revenue:

$133.67M

Net Income/Loss:

$-151.76M

P/E Ratio:

-8.6643

EPS:

-1.4854

Net Cash Flow:

$-124.86M

1W Performance:

+17.75%

1M Performance:

+19.83%

6M Performance:

+73.68%

1Y Performance:

+49.65%

1-Day Range:

$10.02

$13.06

1-Week Range:

$9.97

$13.06

52-Week Range:

$5.635

$13.20

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Name

Day One Biopharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

650 484-0899

Address

1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE

Employee

178

Twitter

Next Earnings Date

Latest SEC Filings

DAWN's Discussions on Twitter

Compare DAWN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DAWN Day One Biopharmaceuticals Inc	12.87	1.04B	133.67M	-151.76M	-124.86M	-1.4854
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Resumed	TD Cowen	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Oct-09-24	Reiterated	Needham	Buy
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy
Apr-24-24	Reiterated	Needham	Buy
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform
Feb-08-23	Initiated	CapitalOne	Overweight
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Dec-05-22	Initiated	Goldman	Buy
Dec-01-22	Initiated	BofA Securities	Buy

View All

Day One Biopharmaceuticals Inc Stock (DAWN) Latest News

03:42 AM

Why Day One Biopharmaceuticals (DAWN) Is Up 17.7% After Positive EU Opinion For OJEMDA Approval - simplywall.st

03:42 AM

Mar 04, 2026

DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise - Stocktwits

Mar 04, 2026

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 26.2%What's Next? - MarketBeat

Mar 04, 2026

Day One Biopharmaceuticals updates presentation after CHMP positive opinion for OJEMDA; 2026 revenue guidance $225–250M - TradingView

Mar 02, 2026

Surging OJEMDA sales and EU backing drive Day One (Nasdaq: DAWN) outlook - Stock Titan

Mar 02, 2026

Feb 28, 2026

Day One Weighs OJEMDA Momentum Against Expanded Oncology Pipeline Risks - Sahm

Feb 28, 2026

DAWN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Feb 28, 2026

Feb 27, 2026

Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead (NASDAQ:DAWN) - Seeking Alpha

Feb 27, 2026

Research Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat

Feb 27, 2026

Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Lowered to Hold at Zacks Research - MarketBeat

Feb 27, 2026